 | |
| Clinical data | |
|---|---|
| Pronunciation | /ˌtraɪləˈsaɪklɪb/ TRY-lə-SY-klib |
| Trade names | Cosela |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Cyclin-dependent kinase (CDK) inhibitor |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C24H30N8O |
| Molar mass | 446.559 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Trilaciclib, sold under the brand name Cosela, is a medication used to reduce chemotherapy-induced bone marrow suppression.[1] Specifically it is used before platinum and etoposide or topotecan treatment for small cell lung cancer.[1] It is given by injection into a vein.[1]
Common side effects include tiredness, low calcium, low potassium, low phosphate, headache, and pneumonia.[1] Other side effects may include allergic reactions, pain at the site of injection, and pneumonitis.[1] Use in pregnancy may harm the baby.[1] It works by temporarily blocking CDK4 and CDK6.[1]
Trilaciclib was approved for medical use in the United States in 2021.[1] It is not available in Europe or the United Kingdom as of 2022.[3] In the United States it costs about 1,600 USD for 300 mg as of 2022.[4]
References edit
- ^ a b c d e f g h i j k l "Cosela- trilaciclib injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 24 June 2021. Retrieved 17 June 2021.
- ^ "FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy". U.S. Food and Drug Administration (FDA) (Press release). 12 February 2021. Archived from the original on 14 June 2021. Retrieved 12 February 2021.
This article incorporates text from this source, which is in the public domain.
- ^ "Trilaciclib". SPS - Specialist Pharmacy Service. 21 August 2020. Archived from the original on 2 February 2022. Retrieved 31 October 2022.
- ^ "Cosela Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 31 October 2022.
